CTXR - Citius Pharmaceuticals, Inc.
IEX Last Trade
3.66
0.280 7.650%
Share volume: 5
Last Updated: Fri 27 Dec 2024 08:29:22 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$3.38
0.28
8.28%
Fundamental analysis
16%
Profitability
0%
Dept financing
5%
Liquidity
45%
Performance
27%
Performance
5 Days
13.75%
1 Month
-8.06%
3 Months
534.22%
6 Months
417.19%
1 Year
319.41%
2 Year
311.18%
Key data
Stock price
$3.66
DAY RANGE
$3.38 - $3.48
52 WEEK RANGE
$0.15 - $4.25
52 WEEK CHANGE
$337.54
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Leonard L. Mazur
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.
Recent news